ALK and non-small cell lung carcinoma: With regard to the incidence of CNS metastases in ALKi-naïve ALK+ NSCLC pts previously treated with chemotherapy, the PROFILE 1007 trial, which compared crizotinib with pemetrexed or docetaxel as a second-line treatment in ALKi-naïve NSCLC pts, showed that the prevalence of BM was approximately 35 % in both arms, which is higher than that observed in the first-line PROFILE 1014 study (Table 1) [5].